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Altered expression of fibrogenic growth factors in IgA nephropathy and
focal and segmental glomerulosclerosis. The profile of fibrogenic growth
factor expression was assessed in biopsies from 27 patients with IgA
nephropathy (IgAN), 14 foeal and segmental glomeruloselerosis (FSGS)
patients and 8 controls, by immunohistochemistry. Increased platelet-
derived growth factor (PDGF)-A and PDGF-B expression was detected in
glomeruli and in vascular structures and collapsed tubules in the intersti-
tium. Computer assisted image analysis demonstrated increased glomer-
ular PDGF-A in IgAN (P < 0.05), but not FSGS patients, compared to
controls, suggesting an association with mesangial proliferation. PDGF
receptors were prominent in areas of mesangial expansion and intertubu-
lar fibrosis. Significant increases in interstitial PDGF Receptor
(PDGFR-fI) were detected for both IgAN (P < 0.01) and FSGS (P < 0.05)
patients. Interstitial PDGFR-13 expression was significantly correlated to
monocyte/macrophage infiltrate (P < 0.0001). Increased basic fibroblast
growth factor (bFGF) expression was observed segmentally in glomeruli,
and in areas of tubulointerstitial damage. Higher proportions of patients
with FSGS than IgAN had elevated interstitial bFGF (P < 0.005) and
PDGF, reflecting the more severe degree of vascular and tubulointerstitial
injury in FSGS patients. This study demonstrates distinct patterns of
fibrogenie growth factors in IgAN and FSGS, strongly associated with the
severity and type of injury.
Glomerulonephritis remains the most common cause of end-
stage renal failure, and the two most common types of GN are
mesangioproliferative IgA nephropathy (IgAN), and focal and
segmental glomerulosclerosis and hyalinosis (FSGS). These forms
of GN contrast not only in pathogenesis but also in glomerular
pathology and rate of decline in renal function: IgAN is charac-
teristically a proliferative form of GN in which only 10 to 20% of
patients develop end-stage renal failure (ESRF) over a period of
5 to 20 years, while FSGS is a nonproliferative GN in which most
patients develop ESRF over a period of 5 to 10 years [I]. These
progressive forms of GN are characterized histologically by
mesangial expansion, varying degrees of glomerular hypercellu-
larity and glomeruloscierosis and are associated with an intersti-
hal inflammatory cell infiltrate, fibrosis, tubular atrophy and
vascular sclerosis [2].
There is increasing evidence that fibrogenic growth factors are
involved in the development of glomerular and interstitial renal
injury in progressive forms of GN [3—101. These growth factors,
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and in particular platelet-derived growth factor (PDGF), basic
fibroblast growth factor (bFGF) and transforming growth factor 13
(TGFf3), are produced by multiple cells including activated mac-
rophages, mesangial cells, endothelial cells, epithelial cells (tubu-
lar and glomerular), smooth muscle cells and mitogen stimulated
fibroblasts, and have chemotactic and mitogenic effects as well as
influence on the accumulation of extracellular matrix. However,
as demonstrated by transfection and infusion studies, the overex-
pression of the different growth factors results in the predomi-
nance of different pathological features. Thus, the most promi-
nent consequence of transfection of TGFI3 in the kidney is
increased accumulation of extracellular matrix (ECM) and gb-
merular sclerosis, while PDGF induces marked mesangial prolif-
eration [11, 12]. Intravenous infusion of bFGF, in contrast, results
in enlargement, vacuolation, and karyomegaly of podocytes in
glomeruli, dilation and cast formation in tubules, as well as
thickening of the media in the lobular arteries. [13]. Basic FGF is
also associated with mesangial cell proliferation in rats pretreated
with subnephritogenic doses of anti-Thy-I antibody [7, 14]. This
suggests that variations in the rate of progression of damage in
different forms of progressive GN may be linked to an altered
fibrogenic growth factor profile. This study investigates the ex-
pression of fibrogenic growth factors in patients with IgAN and
FSGS, and focuses on the relationship between growth factor
expression, interstitial inflammatory cell infiltrate, histopatholog-
ical changes and the overall severity of chronic renal injury.
Methods
Patients and controls
Studies were performed on renal biopsy tissue from 27 patients
with IgAN and 14 patients with FSGS. All biopsies were per-
formed for diagnostic purposes and only a small segment was used
for immunohistochemistry in cases in which there was enough
material. Patient's clinical details are summarized in Table 1.
Control renal tissue was obtained from the pole opposite to the
tumor following a nephrcctomy for renal carcinoma. Only those
tissues with normal morphology were included as controls in this
study.
These studies have been approved by the Human Ethics Review
Committee of the Alfred Group of Hospitals.
Histopathology
Renal biopsies were fixed in 10% buffered formalin and em-
bedded in paraffin for routine histological assessment and frozen
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Table 1. Patients's clinical details
IgAN FSGS Controls
Number of patients 27 14 8
Median age (range) 36 (19—80) 54 (21—74) 56 (42—63)
Reduced creatinine clearance 48%° 79%
< 90 mI/mm
Proteinuria > 150 mg/24 hrs 87% 100%
Nephrotic >3 g/24 hrs
Haematuria > 10 RBC/mm3
23%
96%
42%
38%
Hypertension 57% 83%
a Percentage of patients
in liquid nitrogen for immunofluorescence or immunohistochem-
ical analysis of IgA, lgG, 1gM and C3, C4, C1q and fibrin. Sections
for histopathology were stained with Hematoxylin and Eosin,
Masson trichrome, Silver Masson trichrome and Periodic Acid-
Schiff. All biopsies were also examined by electron microscopy.
The diagnosis of IgAN was established by immunohistochemistry
showing staining of the mesangium.
The results of histopathological examination of the biopsies are
expressed as percentage of 1gAN and FSGS patients demonstrat-
ing varying degrees of severity of histopathological damage in the
glomeruli and the tubulointerstitium.
Immunohistochemical analysis of infiltrating leukocytes, fibrogenic
growth factors and their receptors
A small segment of the renal biopsy was embedded in OCT
medium (Tissue Tek, Bayer Diagnostics) and frozen in liquid
nitrogen. Cryostat sections (4 .r) were cut onto gelatinized slides
and post-fixed with acetone (10 mm at 4°C), paraformaldehyde-
lysine-periodate (PLP) or 4% paraformaldehyde fixative [15].
Acetone and 4% paraformalclehyde fixative were found to best
preserve antigenicity, but morphology was better with the latter.
PLP fixation was adequate for cell surface antigens, PDGF
receptors and bFGF.
The antibodies used in this study are listed in Table 2. A three
or four layer immunoperoxidase technique was used for poly-
clonal or monoclonal antibodies, respectively [18].
Four layer technique. Briefly, nonspecific staining was blocked by
preincubation with 10% normal rabbit serum (NBS), 10% fetal
calf serum (FCS) in PBS with 0.01% sodium azide (Az) for 10
minutes at room temperature (RT). This was followed by over-
night incubation with the primary mouse anti-human antibody at
4°C. After each incubation, slides were washed in phosphate
buffered saline (PBS)-0.2% gelatin. A second layer, goat anti-
mouse IgG (Sigma) was then applied for 30 minutes at RT.
Endogenous peroxidase activity was blocked by incubation for 10
minutes in methanol/0.03% H202, after dehydration through
graded alcohols. After rehydration and washing, slides were
incubated with the third layer, rabbit anti-goat immunoglobulin
(Dako), followed by the fourth layer, goat peroxidasc anti-
peroxidase (Dako), both for 30 minutes at RT. The reaction was
developed by the addition of Metal Enhanced Diaminobenzidine
substrate (Pierce), and slides were counterstained in 1 larris
Hematoxylin, dehydrated, cleared and mounted.
Three layer technique. Sections were preincubated in 10%
normal swine serum (NSS) in PBS/Az. Primary rabbit anti-human
antibodies were incubated overnight at 4°C. Endogenous peroxi-
dase was blocked as described for the 4 layer technique. The
second and third layers were swine anti-rabbit (Dako) and rabbit
peroxidase-anti-peroxidase (Dako), respectively, both incubated
for 30 minutes at room temperature. Washing steps between
incuhations, the development of the reaction, counterstaining and
mounting were performed as described above.
Negative controls included sections where the primary antibody
was omitted for every biopsy. Isotype-specific control monoclonal
antibodies (Dako), or a purified, solid-phase absorbed rabbit
immunoglobulin fraction from healthy non-immunized rabbits
(Dako) were also used. No staining was observed with these
irrelevant antibodies.
Antibody absorption
The specificity of the antibodies to PDGF-A and bFGF was
confirmed by solid phase absorption studies [19]. Microtiter
ELIZA wells were coated with recombinant human PDGF-A
(Genzyme) at a concentration of 50 .tg/ml in 50 m carbonate
buffer, pH 9.6, bFGF (Bachem Inc.) at 0.1 jsg/ml, or carbonate
buffer and incubated overnight at 4°C. The antigen solution was
then removed and nonspecific binding was blocked by incubation
with 1% bovine serum albumin (BSA), 0.02% Az in PBS for two
hours at room temperature. Wells were then washed in three
changes of PBS and allowed to air dry. Rabbit anti-PDGF-AA
(Genzyme) diluted to a final concentration of 10 or 2.5 j.tg/ml,
mouse anti-bFGF (UBI) at 0.5 ig/ml or diluent (1% BSA in PBS)
were then added to the wells and incubated overnight at 4°C. The
supernatants were then harvested and placed on control kidney
sections and staining was carried out as described above. The
lower PDGF-AA antibody concentration (2.5 j.tg/ml) was chosen
as the lowest that retained a strong staining pattern on control
sections after titering out. Wells coated with PDGF-A and bFGF
acted as specificity controls for absorption with anti-bFGF and
anti-PDGF-AA antibodies, respectively. Wells coated with car-
bonate buffer acted as positive controls.
Immunohistochemical assessment of biopsies
The numbers of CD45, CD3 and CD14 leukocytes in the
interstitium and in all glomeruli were counted using an ocular grid
at a magnification of X400. Interstitial infiltrate is expressed as
number of positive cells/mm2. Glomerular infiltrate is expressed
as number of positive cells/glomerulus.
The expression of growth factors and growth factor receptors,
was examined in biopsies and controls. The expression of a
particular antigen was defined as being up-regulated when it was
increased when compared to controls or when biopsies demon-
straterl a pattern of distribution different to that of controls.
Image analysis
The extent of expression of glomerular and interstitial PDGF
receptor (PDGFR)-( and glomerular PDGF-A was evaluated
using a Video Pro computer assisted image analysis system
(Leica), with a Leitz Laborlux S microscope and a Panasonic
digital camera. Results for interstitial staining represent the area
of positive staining in the interstitium expressed as a percentage of
the total interstitial area. Positive staining in the glornerulus was
expressed as a percentage of the area of each glomerulus. All
glomeruli were assessed in each biopsy, and results obtained for
individual glomeruli were averaged for each patient. The expres-
sion of the other growth factors and receptors was not analyzed in
this manner, since the relative lack of definition in the staining
***iii
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Table 2. Antibodies
_______ _______ ________ _______
Antibody Concentration Type Source
71.5 Supernatant Monoclonal Dept. of Medicine [161
90.3.8 Supernatant Monoclonal Dept. of Medicine [171
UCHT-1 3.3 g/ml Monoclonal Dako
05-118 0.5 pg/mI Monoclonal Upstate Biotechnology
Incorporated (UBT)
TGF123 2D7/44 30 pg/mI Monoclonal Biogenesis
PDGF-AA ZP-214 10 sg/ml Polyclonal Genzyme
PDGF-AA 06-130 10 pg/mI Polyclonal UBI
PDGF-BB ZP-215 20 ig/ml Polyclonal Genzyme
PDGFR-f3 Code 1263-00 2 pg/mI Monoclonal Genzyme
PDGFR-cs Code 1264-00 66 pg/mI Monoclonal Genzyme
Histopathology
IgAN FSGS
% of patients
Mesangial proliferationa
Mild 73 57
Moderate 19 0
Severe 4 0
Necrotic lesions 19 0
Crescents 44 0
Glomerulosclerosis
Global 67k' 86
SegmentaP 20 100
Interstitial fibrosis
Mild 42 36
Moderate 27 29
Severe 12 36
Vascular changes
Mild 62 14
Moderate 15 36
Severe 4 29
pattern introduced an unacceptable level of error in the detection
of positive versus negative signals.
Statistics
Statistical analysis was performed using SPSS for Windows.
Comparisons of continuous variables were performed by Kruskall
Wallis ANOVA by ranks, with pairwise comparisons analyzed by
Mann Whitney U-test. Proportions of patients in the different
groups were compared by Pearson's x2 test, with continuity
correction for small sample number. Fisher's two-tailed test was
used when the conditions for x2 statisticswere not met (more than
80% of cells with expected values < 5). Spearman's correlation
was performed for association studies.
Results
Histopathological fratures of patient biopsies
The biopsies demonstrated marked variability in severity of
injury (Table 3). All but one 1gAN patients demonstrated mesan-
gial proliferation, ranging from mild to severe. This was signifi-
cantly greater (P < 0.01) in IgAN compared to FSGS, in which
only mild mesangial hypercellularity was seen in 57% of patients.
All hut one patient, who had IgAN, demonstrated expansion of
E
800
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400
200
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CD45 CD14 CD3
Fig. 1. Interstitial infiainmatoiy cell infiltrate. Individual cells in the inter-
stitium were counted using an ocular grid at a magnification of X400.
Results arc expressed as number of positive cells/mm2. Symbols are: (•)
control; (L) IgAN; (LI) FGS; < 0.05; 'P < 0.01.
mesangial matrix in non scierosed glomeruli. Global and segmen-
tal sclerosis were extensive in FSGS patients, but some degree of
glomerular sclerosis was also seen in 67% of lgAN patients, with
up to 70% of glomeruli involved. Occasional necrotic lesions and
cellular or fibrocellular crescents were observed, but only in IgAN
patients. Interstitial injury ranged from mild interstitial inflamma-
tory cell infiltrate with preserved tubules to moderate or severe
tubular atrophy, interstitial fibrosis and infiltrate. Most patients
demonstrated some degree of vascular damage. Vascular changes
ranged from mild hyaline arteriolar sclerosis and mild arterioscle-
rosis with minimal intimal thickening to severe arteriosclerosis
with marked intimal fibrosis and reduplication of internal elastic
lamina. As shown on Table 3, there was a tendency for FSGS
patients to display more severe vascular and interstitial changes
than IgAN patients.
Inflammatory cell infiltrate
The interstitial inflammatory cell infiltrate ranged from very
mild to severe in both IgAN and FSGS patients (Fig. 1) with an
overall significant increase in CD45 leukocytes in both forms of
glomerulonephritis when compared to control kidneys (P <0.01).
The infiltrate was mainly composed of CDl4 monocytes/macro-
phages and CD3 T cells, though eosinophils were also occasion-
ally evident. Although some patients demonstrated very marked
increases in CD14 cells when compared to controls there was a
wide variability between patients, and no significant differences
were detected by Kruskal Wallis ANOVA by ranks. However, a
___
Specificity
__ __
CD45 (common Icukocyte)
CDI4 (monocytes/macrophages)
CD3 (T cells)
hFGF
Table 3. Histopathological assessment of renal biopsies 1400
1200
1000
P < 0.01 when comparing lgAN and FSGS
h Percentage of patients with one or more glomerulus demonstrating
global or segmental glomerulosclerosis
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Table 4. Glomerular changes
IgAN FSGS Control
CD45 10.2 47a 5.9 1.2 6.9 1.3
CD14 4.2 1.6 2 0.5 1.1 0.3
CD3 0.8 0.4 0.6 0.2 0.8 0.2
PDGF-A 16.7 2.4% c. 7 2.3% 5.1 1.3%
PDGF receptor f3 22.6 2.2% 18.3 3.5% 14.6 1.7%
a Cells per glomerulus (mean SCM)
Percentage positive area as assessed by image analysis
C]) < 0.001 when compared to controls
significant difference in CD14 cell numbers (P < 0.05) was
detected for IgAN patients versus controls when pairwise com-
parisons were performed using the Mann Whitney U-test. The
numbers of interstitial T cells were significantly increased in both
IgAN and FSGS when compared to controls (P < 0.01).
CD3+ infiltrating cells tended to have a focal distribution in the
kidney. In contrast, CD14 monocytes/macrophages had a diffuse
distribution throughout the kidney, particularly localized to areas
of damage in which expression of PDGF receptors was demon-
strated in expanded intertubular areas of the interstitium.
The glomerular inflammatory cell infiltrate is described in
Table 4. No significant increases were demonstrated in either
form of GN when compared to controls.
Fibrogenic growth factors and their receptors
Control human kidneys. Figure 2 depicts the patterns of expres-
sion of growth factors and receptors in control human kidney. All
growth factors were detected on vessels, with bFGF being prom-
inent on endothelial cells (Fig. 2a), and PDGF and TGFI3 being
expressed by vascular smooth muscle cells. bFGF was also seen on
discrete glomerular cells, including mesangial and parietal epithe-
ha! cells of Bowman's capsule (Fig. 2b), and on occasional tubular
cells, with its characteristic localization in the nucleus, as well as
on interstitial cells in the medulla. PDGFR-a was not detected in
controls. In contrast, PDGFR-p was strongly expressed by gb-
merular mesangial cells, occasional parietal epithelial cells and
peritubular interstitial cells (Figs. 2 c, d). PDGF-A was striking in
its distribution along the tubular basement membrane (TBM)
(Fig. 2e). Glomerular staining with anti-PDGF-AA antibodies was
either negative or minimal. Equivalent patterns of expression
were obtained in 4% paraformaldehyde or acetone fixed tissues.
This pattern of PDGF-A expression differs from that described by
Alpers et al i9], possibly due to the harsher conditions of tissue
processing (paraffin-embedded tissue fixed in methyl Carnoy's
fixative) used in that study. Since our initial studies were per-
formed using a Genzyme anti-PDGF-AA antibody, we repeated
our staining using one of the antibodies used by their group, the
UBI rabbit anti-PDGF-AA. No differences were observed in the
staining patterns of these two antibodies, thus confirming our
observation of PDGF-A expression along the TBM.
Antigen-specific solid phase absorption of anti-bFGF (0.5 JLg/
ml) and anti-PDGF-AA antibody at 2.5 tg/ml removed the
staining seen on renal sections. Absorption of the PDGF-AA
antibody at 10 pg/mI resulted in diminished staining, but the
antigen coating the ELIZA wells was not sufficient to completely
abolish reactivity with the tissue section. Incubation in wells
containing either coating buffer only or an irrelevant antigen did
not affect the pattern or intensity of either antibody, thus con-
firming the specificity of the staining.
Up-regulated patterns of expression of growth factors and growth
factor receptors
Despite variations in the degree of up-regulation of growth
factors and receptors between individuals, specific staining pat-
terns were observed for each protein. Figure 3 depicts represen-
tative examples of altered expression of growth factors and
receptors in the glomeruli and in the interstitium.
In the glomerulus, the most striking changes were seen in the
expression of PDGF-A and PDGF receptors. PDGF-A was seen
along the capillary loops, as well as in infiltrating leukocytes and
some intrinsic glomerular cells, possibly mesangial (Fig. 3 a, b).
PDGF receptors were prominent in areas of mesangial expansion
(Fig. 3 c, e). PDGF-B and bFGF (Fig. 3g) were occasionally seen
segmentally in gbomeruli, and TGFI3 was occasionally expressed
by few cells in the glomeruli (Fig. 3i).
In the interstitium, PDGF-A (Fig. 3b) and PDGF-B were
up-regulated in collapsed, atrophied tubules and in vascular
structures. The expression of PDGFR- (Fig. 3d) and in particu-
lar of PDGFR-13 (Fig. 3f) was markedly increased in expanded
intertuhular areas of fibrosis. Basic FGF was increased in areas of
tubular atrophy and interstitial fibrosis, and appeared to be
expressed by tubular epithelial cells as well as by fibroblasts and
myofibroblasts and occasionally infiltrating leukocytes in these
areas (Fig. 3h). TGFI3 expression tended to be very restricted,
with either few infiltrating cells, occasional tubular cells or few
vascular structures showing any significant changes (Fig. 3j).
Expression of growth factors and growth factor receptors in IgAN
and FSGS
Both patient groups demonstrated marked variability in expres-
sion of growth factors and receptors, and the degree of up-
regulation seen in each biopsy appeared to be associated with the
severity of injury, and with the extent of mononuclear cell
infiltrate.
Changes in expression of glomerular PDGF-A and glomerular
and interstitial PDGFR-13 in patients and controls were quantified
by image analysis. As shown on Table 4, glomerular PDGF-A was
significantly increased in patients with IgAN when compared to
controls (P < 0.001), while no significant difference was evident in
the FSGS group. In contrast, no significant differences were
detected between the groups when image analysis of glomerular
PDGFR-13 was performed, while interstitial PDGFR-p was sig-
nificantly increased in both IgAN and FSGS patients when
compared to controls (P < 0.01 and P < 0.05, respectively; Fig. 4).
Further comparisons between IgAN and FSGS patients were
based on the relative proportions of patients with either form of
(IN demonstrating changes in expression of growth factors and
receptors (Table 5). The percentages of FSGS patients with
abnormal expression of growth factors and receptors in the
interstitium was higher than in IgAN, and this attained signifi-
cance for bFGF (P < 0.005), while a clear trend was evident for
PDGF—A and PDGF-B. No significant differences were seen in
the proportions of patients with altered expression of growth
factors in the giomerulus.
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Fig. 2. Expression of fibrogenic growth factors in control human kidneys.(a) Vascular expression of bFGF in the interstitium, with nuclear
localization in endothelial cells. Magnification X255; (b) Expression of
bFGF in parietal epithelial and mesangiat cells in the glomerulus.
Magnification X255; (c) Mesangial expression of PDGFR/3. Magnification
X255; (d) PDGFRI3 in peritubular interstitial cells. Magnification X255;(e) Expression of PDGF-A along the TBM and lack of discrete
glomerular staining. Magnification X 160.
Correlation between interstitial PDGFR-13 expression and CD14
infiltrate
As already stated, the CD14 monocytes/macrophages had a
diffuse distribution throughout the kidney, and were particularly
localized to areas of damage with increased expression of PDGF
receptors in the intcrstitium. To investigate this further, the
expression of PDGFR—p was correlated with CD14 infiltrating
cells in the interstitium. A highly significant positive correlation
was demonstrated, as shown in Figure 5, with a Spearman
correlation coefficient of 0.65 (P < 0.0001).
Discussion
The involvement of fibrogenic growth factors in chronic renal
injury has been demonstrated in a variety of clinical and experi-
mental studies. This study has focused on the expression of
fibrogenic growth factors and their relation to severity of injury in
two contrasting types of GN, IgAN and FSGS. The expression of
growth factors in GN patients was also compared with that seen in
control human kidneys.
PDGF is a potent mitogen and chemoattractant for mescnchy-
mal cells, mesartgial cells and monocytes/macrophages. It causes
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Fig. 3. Altered expression of fibrogenic growth factors in patients with GN. (a) PDGF-A staining along the capillary loops and in the mesangium of a
glomerulus from a patient with IgAN. Magnification x 140; (b) Up-regulation of PDGF-A expression in the glomerulus and in atrophied tubules
(arrowhead) in an IgAN patient. Preserved expression along the TBM. Magnification X140; (c) Up-regulated glomerular expression of PDGFRO in
expanded mesangial areas and staining of peritubular interstitial cells in a patient with JgAN. Magnification X140; (d) Expression of PDGFRa in
expanded intertubular areas in an FSGS patient. Magnification X140; (e) Same patient as in 'c' demonstrating upregulation of PDGFRI3. Magnification
x 140; (f Same patient as in "d", with up-regulated expression of interstitial PDGFR. Magnification x 140; (g) Glomerular expression of bFGF in a
patient with IgAN: nuclear expression of bFGF is evident in parietal epithelial cells, while extracellular bFGF is seen segmentally in the mesangium.
Staining of interstitial cells is also evident. Magnification x220; (h) Interstitial bFGF demonstrated on tubular epithelial cells and interstitial cells in an
FSGS patient. Magnification x 140; (i) Up-regulated expression of TGFI3 in discrete cells within the glomerulus (arrowheads) in an IgAN patient.
Magnification X220; U) Prominent expression of TGFf3 in a partially occluded artery from an IgAN patient. Magnification X 140.
ct 20
It
U)
a 15
0
0
a)
U-0C0
It
U)
C
Control IgAN FSGS
Fig. 4. Interstitial expression of PDGFRI3. The area of positive staining for
PDGFRP in the interstitium was measured by computer assisted image
analysis, as a percentage of the total area of interstitium. Interstitial
PDGFRJ3 was significantly increased in IgAN patients (**P < 0.01), and
in FSGS patients (*P < 0.05) when compared to controls.
cell contraction and stimulates release of other cytokines such as
TGF-13 [9, 20, 21]. Two subunit chains of PDGF, A and B,
combine to form the dimers PDGF AA, BB or AB. PDGFR-a
binds both A and B PDGF chains, and mediates mitogenesis,
while PDGFR-J3 only binds the PDGF-B chain, and mediates
mitogenesis, chemotaxis and circular actin reorganization [22].
In the control kidneys, PDGF-A was prominently demonstrated
along the TBM, as well as in vascular smooth muscle cells in
arteries, also demonstrating PDGF-B. PDGFR-cs was not de-
tected, while PDGFR-J3 was constitutively expressed in glomeru-
lar mesangial cells, occasional parictal epithelial cells and cortical
and niedullary peritubular interstitial cells, as previously described
by Alpers et al [231.
The distribution of PDGF-A along the TBM in patients and
controls and along the glomerular capillary loops in some patients
suggests an association with the ECM. There are two alternative
splice isoforms of PDGF-A, differing in the presence or absence
of a short exon encoding a highly basic carboxyterminal tail. This
results in a shorter isoform, which has been shown to be secreted
efficiently from the producer cell, and a longer isoform (PDGF-
A1) which remains cell associated, and which has been shown to
bind to heparan sulfate proteoglycans in the ECM [22, 24]. Thus,
the PDGF-A detected along TBM may represent the PDGF-AL
variant.
Varying proportions of lgAN and FSGS patients demonstrated
an up-regulation of PDGF ligand and receptors, depending on the
extent and severity of renal damage. Marked changes in expres-
sion of PDGF-A were seen in the glomerulus, where it was
detected in the mesangium and on capillary loops in most
patients. The degree of up-regulation was variable, however, and
image analysis demonstrated a significant increase in PDGF-A
expression in IgAN but not in FSGS with respect to controls. The
strong mitogenic effect of PDGF on mesangial cells suggests the
prominence of this growth factor in IgAN may be linked to the
mesangial proliferation observed in this patient group.
The increases in glomerular expression of PDGF ligand and
receptor 13 observed in this study are in agreement with previous
findings in experimental and clinical glomerulonephritis [3, 8,
25—29]. However, the alterations observed in this study in receptor
expression have not been previously reported in IgAN or FSGS.
In fact, Gesualdo et al [25] were not able to demonstrate this in a
study of biopsies of patients with various forms of GN, other than
in few patients with lupus nephritis. In the same study, they also
report constitutive low level expression of PDGFR-a in glomeruli
and interstitium of controls, which we did not observe. The
presence of very few or no a receptors in conjunction with the
constitutive expression of PDGF-A may represent a mechanism to
prevent the autocrine action of PDGF-A in normal renal tissue, as
suggested by Abboud [30]. In this context, the up-regulation of
PDGFR-a that we demonstrate in disease would represent the
failure of such mechanism, ultimately contributing to the chronic
renal injury.
The up-regulation of PDGF receptors, and particularly of
PDGFR-p in the interstitium was one of the most striking changes
observed in these biopsies. We have observed that in biopsies with
features of tubulointerstitial damage, up-regulation of PDGFR-J3
occurred concomitantly with increased expression of a-smooth
muscle actin, suggesting that the receptor was mainly expressed
on myofibroblasts (data not shown). The increased expression of
PDGF receptors was consistently accompanied by infiltrating
monocytes/macrophagcs, resulting in a highly significant correla-
tion between these pathological features. In contrast, the distri-
bution of T cells was mostly focal and was not spatially associated
with growth factor or receptor expression. Macrophages have
been implicated in the pathogcnesis of various models of renal
disease [reviewed in 311 and are known to produce a number of
cytokines which lead to the activation and proliferation of gb-
merular, tubular and interstitial cells, including myofibroblasts.
These cytokines include TNF-a, IL-1[3, bFGF, TGF13 and PDGF
among others, and their release may be an important factor in
upregulating the expression of PDGFR-13 as detected in this
study. Conversely, fibrogenic growth factors and other cytokines
such as IL-8, macrophage chemotactic peptide (MCP-1) and the
glycoprotein osteopontin released by tubular epithelial cells, other
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Table 5. Expression of growth factors and their receptors in IgAN and FSGS
Growth factor/receptor
_______-
IgAN FSGS
—
TGFPI 30%' 54% 11% 0%
bFGF 33% 28% 30%
PDGF-A 40% 75%' 72% 60%
PDGF-B 32% 67%C 6% 22%
PDGF receptor a 48% 50% 33% 10%
PDGF receptor /3 56% 79% 58% 50%
PDGF receptor 3, % positive area
Fig. 5. Correlation between interstitial PDGFR/3 and monocyte/macrophage
infiltrate. The percentage positive area of PDGFR/3 expression in the
interstitium was assessed by image analysis. The numbers of CD14 cells
(monocytes/macrophages) were counted using an ocular grid at a magni-
fication of X400, and are expressed as cell/mm2. P < 0.0001. Spearman's
correlation was performed using SPSS for Wiiidows.
interstitial cells and by activated myofibroblasts are chemotactic
for the macrophages, and this, together with the up-regulation of
adhesion molecules contributes to their localization in areas of
injury, thus perpetuating and amplifying the activating and fibro-
genie signals in the interstitium.
Basic FGF is a powerful mitogen and chemotactic factor for
mesangial cells, smooth muscle cells, fibroblasts and macrophages
[32, 33], and it has been implicated in various experimental
models of renal disease, particularly in the initiation phase of
mesangial proliferation [7, 8, 10, 34]. There is very little informa-
tion regarding the localization of bFGF in normal kidney, and the
pattern observed in our control kidneys was consistent with our
findings in the rat. There was constitutive expression of bFGF in
vascular endothelial cells, on discrete mesangial and parietal
epithelial cells of Bowman's capsule and on interstitial cells in the
medulla, and a nuclear localization of bFGF was frequently
observed. This compartimentalization can be explained by the
findings of Patty et al [35], who demonstrated that internalized
bFGF in endothelial cells can then be located either in the
cytoplasm or the nucleus, the nuclear translocation occurring in
the late G1 and S phases of the cell cycle. It is of interest that
although the translocation pathway and its biological significance
is not clear, it appears that the presence of FGF in the nucleus can
be correlated with the mitogenic response.
In GN patients, the normal pattern of expression of bFGF was
Interstitium Glomeruli
- -
FSGS
1600
1400
CsE 1200
1000
• 800
'f 600
400
200
0
;.•. ,
I. •
a Percentage of patients with upregulated expression of growth factor/receptorhP < 0.005 Pearsons ,2 test; P < 0.005, continuity correction when comparing IgAN vs. FSGS
cp < 0.05 Pearsons x2 test; P = 0.1, continuity correction when comparing IgAN vs. FSGS
preserved, but additional expression with nuclear, cytoplasmic and
extracytoplasmic localization was observed in some patients. In
the glomerulus, bFGF protein was seen most strikingly in areas of
• • segmental expansion of mesangial matrix, suggesting its release
from injured cells and its association with the ECM. In the
interstitium it was prominent in areas of tubulointerstitial dam-
age. There was a significantly higher percentage of FSGS patients
demonstrating altered interstitial expression of bFGF than of
IgAN patients. The finding by Mazue et al [13], that intravenous
_______________________________________________ infusion of bFGF results in tubular and vascular damage, suggests
0 5 10 15 20 25 30 35 40 the prevalence of interstitial bFGF in FSGS may be a contributing
factor to the increased severity of vascular injury and tubular
atrophy/interstitial fibrosis in this patient group.
TGF13 is a multifunctional growth factor, synthesized by many
cell types including renal tubular epithelial cells, mesangial cells
and macrophages [9, 36, 37]. It has important effects resulting in
the accumulation of extracellular matrix, and is also a strong
chemoattractant for monocytes/macrophages and fibroblasts.
TGFJ3 has been implicated in the development of injury in GN [8,
28, 38—42]. We have also detected increased expression of TGF/3
mRNA in chronic renal allograft rejection [43] and in the 7/8
nephrectomy model of FSGS [44]. The limited expression of
TGFI3 detected in biopsies of patients with GN was therefore
unexpected, and may reflect the specificity of the monoclonal
antibody used in this study, which may not recognize all active or
latent forms of TGF/3. In fact, different staining patterns obtained
with antibodies to different epitopes of TGFI31 have been de-
scribed previously [45].
In conclusion, this study has demonstrated elevated expression
of PDGF, PDGF receptors and bFGF in patients with IgAN and
FSGS. Specific patterns of up-regulation were evident, strongly
associated with the severity and type of injury. The active involve-
ment of monocytes/macrophages in the development of chronic
injury was confirmed by a strong correlation between their
numbers and localization in the interstitium and the phenotypic
change of fibroblasts to myofibroblasts, with strong expression of
PDGF receptors. The expression of PDGF-A in the glomerulus
was up-regulated in IgAN as compared to FSGS patients, sug-
gesting an association with mesangial proliferation. Conversely,
FSGS patients demonstrated higher expression of PDGF-A and
-B as well as bFGF in the interstitium, reflecting the relatively
more severe degree of vascular and tubulointerstitial injury seen
in this patient group. In contrasting these two different types of
GN, this study was thus able to identify links between overexpres-
sion of particular growth factors in the various compartments of
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the kidney with associated injury, and in this way contributes to
the definition of the relevant pathways of damage in renal disease.
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